Bank of America began coverage on shares of Personalis (NASDAQ:PSNL) in a report published on Monday, BenzingaRatingsTable reports. The firm issued a neutral rating and a $27.00 price objective on the stock.
PSNL opened at $21.40 on Monday. Personalis has a 1 year low of $20.21 and a 1 year high of $31.88.
In related news, Director Ken Ludlum bought 70,000 shares of the business’s stock in a transaction dated Monday, June 24th. The stock was purchased at an average cost of $17.00 per share, for a total transaction of $1,190,000.00. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website.
Personalis Company Profile
Personalis, Inc operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies. It offers NeXT Platform, which provides data for cancer therapy development, personalized therapies, therapy selection, and diagnostics.
Featured Story: CBOE Russell 2000® Volatility Index
Receive News & Ratings for Personalis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Personalis and related companies with MarketBeat.com's FREE daily email newsletter.